Enzyme-Linked DNA Displacement (ELIDIS) Assay as an innovative immunoassay platform

Develop and validate a novel immunoassay, ELIDIS, as a portable, efficient alternative to ELISA for biotech and biopharma applications, enhancing accessibility and ease of use.

Subsidie
€ 150.000
2024

Projectdetails

Since its introduction more than 50 years ago, ELISA (Enzyme-Linked Immunosorbent Assay) remains one of the most widely used technologies for research, drug discovery, and diagnosis.

Introduction

The reasons for this extraordinary longevity are manifold: ELISA combines the high specificity of antibody-antigen interactions with the high sensitivity of enzyme amplification. However, ELISA also has disadvantages: multiple washing steps and reagents are required, and a specialized instrument is needed, which is not always available in all laboratories. An innovative immunoassay technology that can overcome the limitations of ELISA while retaining all of its best features would therefore represent a turning point in the global immunoassay market (> $35 billion in 2023).

Development of ELIDIS

Under the ERC Consolidator Grant PRO-TOOLKITS, we have developed a novel immunoassay, which we have named Enzyme-Linked DNA Displacement (ELIDIS). This technology has all the characteristics to meet the need for an alternative to ELISA.

Overview of ELIDIS

In short, ELIDIS involves two steps and is based on the use of enzyme-conjugated DNA strands and disposable electrodes. ELIDIS retains the advantageous properties of ELISA (high sensitivity and specificity) but, unlike ELISA, is easier to perform. It does not require enzyme-labeled antibodies and, more importantly, can be performed using portable electronic devices such as a laptop or smartphone without the need for additional instruments.

Project Goals

With these considerations in mind, in this PoC project we will validate the ELIDIS assay as a candidate to replace ELISA in any biotech and biopharma laboratory. To achieve this goal, we will:

  1. Validate the ELIDIS assay for the detection of two model targets (Trastuzumab and EGFR).
  2. Develop two prototype kits using disposable sensor arrays and a portable device (or an app/software).
  3. Create a “manufacturing plan” for assay production.
  4. Develop an IP strategy for patent filing/maintenance.
  5. Create a plan for business/commercialization.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-11-2024
Einddatum30-4-2026
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • ISTITUTO NAZIONALE DI BIOSTRUTTURE E BIOSISTEMIpenvoerder

Land(en)

Italy

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

ELECTROCHEMICAL DNA-BASED SENSORS FOR IMMUNOTHERAPY MONITORING

The project aims to evaluate the commercial potential of a novel DNA-based platform for rapid and cost-effective detection of bispecific antibodies to monitor immunotherapy efficacy.

€ 150.000
ERC Proof of...

self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnostics

PRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries.

€ 150.000
ERC Proof of...

Fast and simple biomarker detection by computational microscopy

We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.

€ 150.000
ERC Proof of...

CRISPR Point-of-Care Diagnostics

Developing a streamlined, one-step CRISPR-Cas diagnostic tool for rapid and accurate detection of COPD pathogens, enhancing point-of-care diagnostics and commercialization potential.

€ 150.000
ERC Proof of...

High-throughput combinatory drugs testing on in vitro 3D cells model platform

The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.

€ 150.000

Vergelijkbare projecten uit andere regelingen

EIC Transition

Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization

Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.

€ 2.226.280
EIC Pathfinder

ECL-based Infectious Pathogen (bio)SEnsor

ECLIPSE aims to develop a portable, cost-effective platform using ultrasensitive detection methods for rapid identification of infectious pathogens, enhancing response to future pandemics.

€ 2.683.996
EIC Transition

Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to Lab

BiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening.

€ 2.500.000
EIC Transition

Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics

Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.

€ 2.498.125
Mkb-innovati...

IncoTIME

Het project richt zich op het verbeteren van het coatingsproces voor microfluïdische cartridges, met als doel een schaalbaar en economisch productieprotocol voor Point of Care diagnostische testen te ontwikkelen.

€ 180.950